论文部分内容阅读
目的:运用循证医学的方法学原理,对中国非小细胞肺癌患者ERCC1表达与铂类药物疗效相关性进行评价,为肿瘤的个体化治疗提供一定的理论依据及策略。方法:检索2011-02前发表的中英文数据库,纳入中国人群ERCC1表达与基于铂类化疗方案疗效的临床对照研究。采用RevMan 4.2.8软件进行数据处理。结果:共纳入17项研究,累计病例1 293例,其中ERCC1阳性表达611例,ERCC1阴性表达682例。异质性检验显示,χ2=11.45,P=0.41;采用随机效应模型,合并OR值为2.82,95%CI:2.12～3.74,P<0.000 01。能接受纳入研究的偏倚,P=0.244。结论:ERCC1阴性表达与铂类药物化疗的疗效有很好的相关性。由于各研究报道的生存时间单位不统一无法合并,因此,对生存期的预测还不能完全确定。
OBJECTIVE: To evaluate the relationship between the expression of ERCC1 and the efficacy of platinum-based drugs in patients with non-small cell lung cancer (NSCLC) based on the methodological principles of evidence-based medicine and to provide some theoretical basis and strategies for the individualized treatment of cancer. Methods: The Chinese-English database published before 2011-02 was retrieved and included in the clinical control study of the ERCC1 expression in Chinese population and the efficacy of platinum-based chemotherapy. RevMan 4.2.8 software for data processing. Results: A total of 17 studies were included, of which 1 293 cases were cumulative, of which 611 were ERCC1 positive and 682 were ERCC1 negative. Heterogeneity test showed that χ2 = 11.45, P = 0.41; using random effects model, the combined OR was 2.82, 95% CI: 2.12 ~ 3.74, P <0.0001. Can be included in the study of bias, P = 0.244. Conclusion: The negative expression of ERCC1 has a good correlation with the efficacy of platinum-based chemotherapy. As the survival time units reported in each study are not uniform unit can not be combined, therefore, the prediction of survival can not be completely determined.